炎症性肠病缓解期患者的腹痛:一项影响因素的前瞻性研究。

IF 6.6 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Alimentary Pharmacology & Therapeutics Pub Date : 2023-09-19 DOI:10.1111/apt.17718
L. M. Janssen, A. Rezazadeh Ardabili, M. J. L. Romberg-Camps, B. Winkens, R. J. van den Broek, J. Hulst, H. J. A. Verwijs, D. Keszthelyi, D. M. A. E. Jonkers, A. A. van Bodegraven, M. J. Pierik, Z. Mujagic
{"title":"炎症性肠病缓解期患者的腹痛:一项影响因素的前瞻性研究。","authors":"L. M. Janssen,&nbsp;A. Rezazadeh Ardabili,&nbsp;M. J. L. Romberg-Camps,&nbsp;B. Winkens,&nbsp;R. J. van den Broek,&nbsp;J. Hulst,&nbsp;H. J. A. Verwijs,&nbsp;D. Keszthelyi,&nbsp;D. M. A. E. Jonkers,&nbsp;A. A. van Bodegraven,&nbsp;M. J. Pierik,&nbsp;Z. Mujagic","doi":"10.1111/apt.17718","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Abdominal pain is highly prevalent in patients with inflammatory bowel disease (IBD) in remission, but the aetiology is incompletely understood.</p>\n </section>\n \n <section>\n \n <h3> Aim</h3>\n \n <p>To investigate the association of clinical, lifestyle and psychosocial factors with abdominal pain in patients with IBD in remission.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We performed a prospective multicentre study enrolling consecutive patients with IBD. Data were collected between 1 January 2020 and 1 July 2021, using myIBDcoach, an established remote monitoring platform for IBD. Chronic abdominal pain in IBD in remission (IBD<i>remission</i>Pain+) was defined as abdominal pain score ≥3 (0–10 NRS) on ≥1/3 of all assessments, combined with faecal calprotectin &lt;150 μg/g in 90 days around periodic assessments. Disease activity, lifestyle and psychosocial factors were assessed every 1–3 months during 18 months. Using linear mixed models, the association of these factors with abdominal pain over time was analysed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We included 559 patients, of whom 429 (76.7%) remained in biochemical remission. Of these, 198 (46.2%) fulfilled the criteria for chronic abdominal pain. IBD<i>remission</i>Pain+ patients were characterised by female sex, younger age, higher BMI, and shorter disease duration. They reported more often or higher levels of stress, fatigue, depressive and anxiety symptoms, and life events (all <i>p</i> &lt; 0.001). In the multivariable analysis, sex, disease entity, fatigue, depressive symptoms and life events were associated with abdominal pain over time (all <i>p</i> &lt; 0.05).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>In this cohort of patients with IBD in remission, abdominal pain was common and associated with psychosocial factors. A more holistic treatment approach for patients with IBD suffering from abdominal pain may improve quality of care and subjective wellbeing.</p>\n </section>\n </div>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"58 10","pages":"1041-1051"},"PeriodicalIF":6.6000,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.17718","citationCount":"3","resultStr":"{\"title\":\"Abdominal pain in patients with inflammatory bowel disease in remission: A prospective study on contributing factors\",\"authors\":\"L. M. Janssen,&nbsp;A. Rezazadeh Ardabili,&nbsp;M. J. L. Romberg-Camps,&nbsp;B. Winkens,&nbsp;R. J. van den Broek,&nbsp;J. Hulst,&nbsp;H. J. A. Verwijs,&nbsp;D. Keszthelyi,&nbsp;D. M. A. E. Jonkers,&nbsp;A. A. van Bodegraven,&nbsp;M. J. Pierik,&nbsp;Z. Mujagic\",\"doi\":\"10.1111/apt.17718\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Abdominal pain is highly prevalent in patients with inflammatory bowel disease (IBD) in remission, but the aetiology is incompletely understood.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Aim</h3>\\n \\n <p>To investigate the association of clinical, lifestyle and psychosocial factors with abdominal pain in patients with IBD in remission.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We performed a prospective multicentre study enrolling consecutive patients with IBD. Data were collected between 1 January 2020 and 1 July 2021, using myIBDcoach, an established remote monitoring platform for IBD. Chronic abdominal pain in IBD in remission (IBD<i>remission</i>Pain+) was defined as abdominal pain score ≥3 (0–10 NRS) on ≥1/3 of all assessments, combined with faecal calprotectin &lt;150 μg/g in 90 days around periodic assessments. Disease activity, lifestyle and psychosocial factors were assessed every 1–3 months during 18 months. Using linear mixed models, the association of these factors with abdominal pain over time was analysed.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>We included 559 patients, of whom 429 (76.7%) remained in biochemical remission. Of these, 198 (46.2%) fulfilled the criteria for chronic abdominal pain. IBD<i>remission</i>Pain+ patients were characterised by female sex, younger age, higher BMI, and shorter disease duration. They reported more often or higher levels of stress, fatigue, depressive and anxiety symptoms, and life events (all <i>p</i> &lt; 0.001). In the multivariable analysis, sex, disease entity, fatigue, depressive symptoms and life events were associated with abdominal pain over time (all <i>p</i> &lt; 0.05).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>In this cohort of patients with IBD in remission, abdominal pain was common and associated with psychosocial factors. A more holistic treatment approach for patients with IBD suffering from abdominal pain may improve quality of care and subjective wellbeing.</p>\\n </section>\\n </div>\",\"PeriodicalId\":121,\"journal\":{\"name\":\"Alimentary Pharmacology & Therapeutics\",\"volume\":\"58 10\",\"pages\":\"1041-1051\"},\"PeriodicalIF\":6.6000,\"publicationDate\":\"2023-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.17718\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alimentary Pharmacology & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/apt.17718\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apt.17718","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 3

摘要

背景:腹痛在炎症性肠病(IBD)缓解期患者中非常普遍,但其病因尚不完全清楚。目的:探讨临床、生活方式和心理社会因素与IBD缓解期患者腹痛的关系。方法:我们进行了一项前瞻性多中心研究,纳入了连续的IBD患者。数据是在2020年1月1日至2021年7月1日期间使用myIBDcoach收集的,myIBDoach是一个已建立的IBD远程监测平台。IBD缓解期的慢性腹痛(IBDremissionPain+)定义为所有评估中≥1/3的腹痛评分≥3(0-10 NRS),并结合粪便钙卫蛋白。结果:我们纳入559名患者,其中429名(76.7%)仍处于生化缓解状态。其中198例(46.2%)符合慢性腹痛的标准。IBDremissionPain+患者的特点是女性、年龄较小、BMI较高、病程较短。他们报告了更频繁或更高水平的压力、疲劳、抑郁和焦虑症状以及生活事件(均p 结论:在这组IBD缓解期患者中,腹痛很常见,并与心理社会因素有关。对患有腹痛的IBD患者采用更全面的治疗方法可能会提高护理质量和主观幸福感。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Abdominal pain in patients with inflammatory bowel disease in remission: A prospective study on contributing factors

Background

Abdominal pain is highly prevalent in patients with inflammatory bowel disease (IBD) in remission, but the aetiology is incompletely understood.

Aim

To investigate the association of clinical, lifestyle and psychosocial factors with abdominal pain in patients with IBD in remission.

Methods

We performed a prospective multicentre study enrolling consecutive patients with IBD. Data were collected between 1 January 2020 and 1 July 2021, using myIBDcoach, an established remote monitoring platform for IBD. Chronic abdominal pain in IBD in remission (IBDremissionPain+) was defined as abdominal pain score ≥3 (0–10 NRS) on ≥1/3 of all assessments, combined with faecal calprotectin <150 μg/g in 90 days around periodic assessments. Disease activity, lifestyle and psychosocial factors were assessed every 1–3 months during 18 months. Using linear mixed models, the association of these factors with abdominal pain over time was analysed.

Results

We included 559 patients, of whom 429 (76.7%) remained in biochemical remission. Of these, 198 (46.2%) fulfilled the criteria for chronic abdominal pain. IBDremissionPain+ patients were characterised by female sex, younger age, higher BMI, and shorter disease duration. They reported more often or higher levels of stress, fatigue, depressive and anxiety symptoms, and life events (all p < 0.001). In the multivariable analysis, sex, disease entity, fatigue, depressive symptoms and life events were associated with abdominal pain over time (all p < 0.05).

Conclusion

In this cohort of patients with IBD in remission, abdominal pain was common and associated with psychosocial factors. A more holistic treatment approach for patients with IBD suffering from abdominal pain may improve quality of care and subjective wellbeing.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
15.60
自引率
7.90%
发文量
527
审稿时长
3-6 weeks
期刊介绍: Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
期刊最新文献
Development and Validation of a PIVKA-II-Based Model for HCC Risk Stratification in Patients With HCV-Related Cirrhosis Successfully Treated With DAA Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease? Editorial: Updated COVID-19 Boosters-Tailoring Protection for Patients With IBD. Authors' Reply. Review Article: Green Management of IBD-New Paradigms for an Eco-Friendly Approach. Subcutaneous Infliximab Concentration Thresholds for Mucosal and Transmural Healing in Patients With Crohn's Disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1